← Eichor
Study identifier: NCT06230055 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

Condition: HER2-negative Breast Cancer · Leptomeningeal Metastasis  ·  Sponsor: Fudan University

PhasePhase 4
Planned participants37
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective, multicenter, randomized controlled, open-label investigator-initiated clinical study to evaluate the clinical efficacy and quality of life of intrathecal chemotherapy through Ommaya reservoir in combination with systematic chemotherapy versus systemic chemotherapy alone in patients with Her-2 negative breast cancer with leptomeningeal metastasis.

This description comes directly from the study's public registry record.

Talk to the study team

Jian Zhang  ·  +8664175590  ·  syner2000@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06230055